WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007008603) MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/008603    International Application No.:    PCT/US2006/026352
Publication Date: 18.01.2007 International Filing Date: 07.07.2006
IPC:
A61K 38/00 (2006.01)
Applicants: SEATTLE GENETICS, INC. [US/US]; 21823 30th Drive SE, Bothell, WA 98021 (US) (For All Designated States Except US).
DORONINA, Svetlana, O. [RU/US]; (US) (For US Only).
KLINE, Toni, Beth [US/US]; (US) (For US Only)
Inventors: DORONINA, Svetlana, O.; (US).
KLINE, Toni, Beth; (US)
Agent: HOPKINS, Mark, H.; TOWNSEND and TOWNSEND and CREW LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US)
Priority Data:
60/697,767 07.07.2005 US
Title (EN) MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
(FR) COMPOSES DE MONOMETHYLVALINE PRESENTANT DES MODIFICATIONS DE LA CHAINE LATERALE DE PHENYLALANINE AU NIVEAU DE L'EXTREMITE C
Abstract: front page image
(EN)Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The rlated conjugates can target specific cell types to provide therapeutic benefit.
(FR)La présente invention se rapporte à des analogues peptidiques de l'auristatine MeVal-Val-Dil-Dap-Phe (MMAF), qui présentent des substitutions ou des modifications de la chaîne latérale du résidu phénylalanine C-terminal, et qui sont soit seuls soit liés à des ligands par l'intermédiaire de divers lieurs. Les conjugués associés peuvent cibler des types de cellules spécifiques pour apporter un bénéfice thérapeutique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)